Core Viewpoint - Artiva Biotherapeutics, Inc. is set to present at the 24th Annual Needham Virtual Healthcare Conference on April 7, 2025, highlighting its focus on developing cell therapies for autoimmune diseases and cancers [1][2]. Company Overview - Artiva Biotherapeutics is a clinical-stage biotechnology company founded in 2019, specializing in cell therapies for autoimmune diseases and cancers [3]. - The company's lead program, AlloNK, is an allogeneic, off-the-shelf, non-genetically modified, cryopreserved NK cell therapy candidate aimed at enhancing the efficacy of monoclonal antibodies for B-cell depletion [3]. - AlloNK is currently undergoing clinical trials for systemic lupus erythematosus and is involved in an investigator-initiated basket trial for multiple autoimmune indications [3]. - Artiva's pipeline also includes CAR-NK candidates targeting both solid and hematologic cancers [3]. - The company has exclusive worldwide rights (excluding Asia, Australia, and New Zealand) to GC Cell's NK cell manufacturing technology and programs, following a strategic partnership [3]. Event Participation - Members of the Artiva management team will engage in investor meetings during the conference, and a live webcast of the presentation will be available for the public [2]. - A replay of the webcast will be accessible for 90 days post-event [2]. Contact Information - For investor inquiries, Neha Krishnamohan can be contacted at ir@artivabio.com, and for media inquiries, Jessica Yingling, Ph.D., can be reached at jessica@litldog.com or +1.858.344.8091 [6].
Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference